Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile
10.1124/jpet.109.151639
Crossref journal-article
Elsevier BV
The Journal of Pharmacology and Experimental Therapeutics (78)
Bibliography

Gavaldà, A., Miralpeix, M., Ramos, I., Otal, R., Carreño, C., Viñals, M., Doménech, T., Carcasona, C., Reyes, B., Vilella, D., Gras, J., Cortijo, J., Morcillo, E., Llenas, J., Ryder, H., & Beleta, J. (2009). Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile. The Journal of Pharmacology and Experimental Therapeutics, 331(2), 740–751.

Authors 16
  1. Amadeu Gavaldà (first)
  2. Montserrat Miralpeix (additional)
  3. Israel Ramos (additional)
  4. Raquel Otal (additional)
  5. Cristina Carreño (additional)
  6. Marisa Viñals (additional)
  7. Teresa Doménech (additional)
  8. Carla Carcasona (additional)
  9. Blanca Reyes (additional)
  10. Dolors Vilella (additional)
  11. Jordi Gras (additional)
  12. Julio Cortijo (additional)
  13. Esteban Morcillo (additional)
  14. Jesús Llenas (additional)
  15. Hamish Ryder (additional)
  16. Jorge Beleta (additional)
References 38 Referenced 103
  1. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, et al.. (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578. (10.1038/sj.bjp.0706780)
  2. Belmonte KE (2005) Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:297–304, discussion 311–312. (10.1513/pats.200504-043SR)
  3. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, and Herings RM (2007) Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med 101:1398–1405. (10.1016/j.rmed.2007.01.025)
  4. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, and Witek T, Jr. (2002) A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19:217–224. (10.1183/09031936.02.00269802)
  5. Cazzola M and Matera MG (2008) Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 155:291–299. (10.1038/bjp.2008.284)
  6. Cereda E, Ezhaya A, Gil Quintero M, Bellora E, Dubini E, Micheletti R, Schiavone A, Brambilla A, Schiavi GB, and Donetti A (1990) Synthesis and biological evaluation of new antimuscarinic compounds with amidine basic centers. A useful bioisosteric replacement of classical cationic heads. J Med Chem 33:2108–2113. (10.1021/jm00170a010)
  7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108. (10.1016/0006-2952(73)90196-2)
  8. Copeland RA, Pompliano DL, and Meek TD (2006) Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 5:730–739. (10.1038/nrd2082)
  9. Cortijo J, Sanz CM, Villagrasa V, Morcillo EJ, and Small RC (1994) The effects of phorbol 12,13-diacetate on responses of guinea-pig isolated trachea to methylxanthines, isoprenaline and ryanodine. Br J Pharmacol 111:769–776. (10.1111/j.1476-5381.1994.tb14804.x)
  10. Disse B, Reichl R, Speck G, Traunecker W, Ludwig Rominger KL, and Hammer R (1993) Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci 52:537–544. (10.1016/0024-3205(93)90312-Q)
  11. Dowling MR and Charlton SJ (2006) Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol 148:927–937. (10.1038/sj.bjp.0706819)
  12. Eglen RM (2005) Muscarinic receptor subtype pharmacology and physiology. Prog Med Chem 43:105–136. (10.1016/S0079-6468(05)43004-0)
  13. Gavaldà A, Miralpeix M, Ramos I, Vilella D, Sentellas S, Alberti J, Ryder H, and Beleta J (2007) Aclidinium bromide, a novel muscarinic receptor combining long residence at M3 receptors and rapid plasma clearance. Eur Respir J 30 (Suppl 51):209S–210S.
  14. Gavaldà A, Sentellas S, Alberti J, Anton SF, Salva M, and Beleta J (2008) Aclidinium bromide, a novel long-acting anticholinergic, is rapidly inactivated in plasma. Am J Respir Crit Care Med 177:A654.
  15. Gras J, Gavaldà A, and Llenas J (2008) The preclinical cardiovascular safety profile of aclidinium bromide, a novel long-acting anticholinergic drug. Am J Resp Crit Care Med 177:A654.
  16. Gross NJ (2006) Anticholinergic agents in asthma and COPD. Eur J Pharmacol 533:36–39. (10.1016/j.ejphar.2005.12.072)
  17. Gwilt CR, Donnelly LE, and Rogers DF (2007) The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol Ther 115:208–222. (10.1016/j.pharmthera.2007.05.007)
  18. Haddad EB, Mak JC, and Barnes PJ (1994) Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 45:899–907. (10.1016/S0026-895X(25)10204-6)
  19. Hanania NA and Donohue JF (2007) Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc 4:526–534. (10.1513/pats.200701-016FM)
  20. Konzett H and Rossler R (1940) Versuchsanorndnung zu untersuchungen an der bronchialmuskulatur. Arch Exp Pathol Pharmakol 195:71–74. (10.1007/BF01861842)
  21. Lieberman JA, 3rd (2004) Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry 6:20–23.
  22. Lee TA, Pickard AS, Au DH, Bartle B, and Weiss KB (2008) Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 149:380–390. (10.7326/0003-4819-149-6-200809160-00004)
  23. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, and Buist S (2006) Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27:397–412. (10.1183/09031936.06.00025805)
  24. Mathers CD and Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442. (10.1371/journal.pmed.0030442)
  25. Minette PA and Barnes PJ (1988) Prejunctional inhibitory muscarinic receptors on cholinergic nerves in human and guinea pig airways. J Appl Physiol 64:2532–2537. (10.1152/jappl.1988.64.6.2532)
  26. Misawa M, Ohmori S, and Yanaura S (1986) Effects of the new antiallergic drug 11-oxo-11 H-pyrido[2,1-b] quinazoline-2-carboxylic acid on bronchial and cutaneous allergic responses to ascaris in dogs. Arzneimittelforschung 36:1647–1650.
  27. Nials AT, Summer MJ, Johnson M, and Coleman RA (1993) Investigations into factors determining the duration of action of beta 2-adenoceptor agonist, salmeterol. Br J Pharmacol 108:507–515. (10.1111/j.1476-5381.1993.tb12833.x)
  28. Prat M, Fernández D, Buil MA, Crespo MI, Casals G, Ferrer M, Tort L, Castro J, Monleón JM, Gavaldà A, et al.. (2009) Discovery of novel quaternary ammonium derivatives of (3 R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3 R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide). J Med Chem doi:10.1021/jm900132z. (10.1021/jm900132z)
  29. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al.. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532–555. (10.1164/rccm.200703-456SO)
  30. Roffel AF, Elzinga CR, and Zaagsma J (1990) Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 3:47–51. (10.1016/0952-0600(90)90009-8)
  31. Takahashi T, Belvisi MG, Patel H, Ward JK, Tadjkarimi S, Yacoub MH, and Barnes PJ (1994) Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 150:1640–1645. (10.1164/ajrccm.150.6.7952627)
  32. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, and Decramer M UPLIFT Study Investigators (2008) A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359:1543–1554. (10.1056/NEJMoa0805800)
  33. Villetti G, Bergamaschi M, Bassani F, Bolzoni PT, Harrison S, Gigli PM, Janni A, Geppetti P, Civelli M, and Patacchini R (2006) Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol 148:291–298. (10.1038/sj.bjp.0706724)
  34. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, and Cornelissen PJ Dutch/Belgian Tiotropium Study Group (2002) Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 19:209–216. (10.1183/09031936.02.00238702)
  35. Wess J, Eglen RM, and Gautam D (2007) Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov 6:721–733. (10.1038/nrd2379)
  36. Gavaldà A, Miralpeix M, Ramos I, Vilella D, Sentellas S, Albertí J, Ryder H, and Beleta J (2007) Aclidinium bromide, a novel muscarinic receptor antagonist combining long residence at M3 receptors and rapid plasma clearance. Eur Respir J 30 (Suppl 51):209S–s10S. European Respiratory Society Annual Meeting; 2007 Sept 15–19; Stockholm, Sweden. European Respiratory Society, Lausanne, Switzerland.
  37. Miralpeix M, Gavaldà A, Morcillo E, Cortijo J, Puig J, Ryder H, and Beleta J (2007) Assessment of the potency and duration of action of aclidinium bromide in guinea pig isolated trachea in vitro. Eur Respir J 30 (Suppl 51):359S. European Respiratory Society Annual Meeting; 2007 Sept 15–19; Stockholm, Sweden. European Respiratory Society, Lausanne, Switzerland.
  38. Miralpeiz M, Otal R, Carreño C, Reyes B, Carcasona C, Llenas J, Ryder H, Beleta J, and Gavaldà A (2008) Aclidinium bromide, a novel anti-muscarinic, reverses cholinergic-induced bronchoconstriction with a fast onset of action and a long-lasting effect in guinea pigs. Am J Respir Crit Care Med 177:A654. American Thoracic Society Annual Meeting; 2008 May 16–21; Toronto, ON, Canada. American Thoracic Society, New York, NY.
Dates
Type When
Created 16 years ago (Aug. 26, 2009, 10:14 p.m.)
Deposited 6 months, 2 weeks ago (Feb. 19, 2025, 8:38 p.m.)
Indexed 1 month, 3 weeks ago (July 11, 2025, 6:14 a.m.)
Issued 15 years, 10 months ago (Nov. 1, 2009)
Published 15 years, 10 months ago (Nov. 1, 2009)
Published Print 15 years, 10 months ago (Nov. 1, 2009)
Funders 0

None

@article{Gavald__2009, title={Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile}, volume={331}, ISSN={0022-3565}, url={http://dx.doi.org/10.1124/jpet.109.151639}, DOI={10.1124/jpet.109.151639}, number={2}, journal={The Journal of Pharmacology and Experimental Therapeutics}, publisher={Elsevier BV}, author={Gavaldà, Amadeu and Miralpeix, Montserrat and Ramos, Israel and Otal, Raquel and Carreño, Cristina and Viñals, Marisa and Doménech, Teresa and Carcasona, Carla and Reyes, Blanca and Vilella, Dolors and Gras, Jordi and Cortijo, Julio and Morcillo, Esteban and Llenas, Jesús and Ryder, Hamish and Beleta, Jorge}, year={2009}, month=nov, pages={740–751} }